OBJECTIVE: To test the hypothesis that: (i) functional microvascular dilator capacity is independently associated with insulin sensitivity and age in individuals with central adiposity at risk of cardiovascular disease (CVD); and (ii) functional microvascular dilator capacity is improved by high dose statin treatment. METHODS:Functional dilator capacity (measured as change in laser Doppler blood flux from baseline during post occlusive reactive hyperemia [peak flux%resting flux; PF%RF] and flowmotion (power spectral density [PSD] analysis)) were assessed in 40 people with central adiposity and one or more other CVD risk factors. Measurements were made at rest and during acute hyperinsulinaemia before and six months after high dose atorvastatin (40 mg daily) or placebo. RESULTS: Insulin-induced change in PF%RF was independently associated with insulin sensitivity (M/I) (r = 0.46 p = 0.02) and age (r = -0.46 p = 0.02), which together explained almost half of the variance in PF%RF (adjusted r² = 0.37, p = 0.008). Whilst atorvastatin decreased LDL cholesterol by 51% (p < 0.001), PF%RF and flowmotion remained unchanged. CONCLUSIONS:Insulin sensitivity and age are independently associated with an insulin-induced change in functional microvascular dilator capacity in individuals with central adiposity at risk of CVD. Dilator capacity is not improved by six months high dose statin treatment.
RCT Entities:
OBJECTIVE: To test the hypothesis that: (i) functional microvascular dilator capacity is independently associated with insulin sensitivity and age in individuals with central adiposity at risk of cardiovascular disease (CVD); and (ii) functional microvascular dilator capacity is improved by high dose statin treatment. METHODS: Functional dilator capacity (measured as change in laser Doppler blood flux from baseline during post occlusive reactive hyperemia [peak flux%resting flux; PF%RF] and flowmotion (power spectral density [PSD] analysis)) were assessed in 40 people with central adiposity and one or more other CVD risk factors. Measurements were made at rest and during acute hyperinsulinaemia before and six months after high dose atorvastatin (40 mg daily) or placebo. RESULTS:Insulin-induced change in PF%RF was independently associated with insulin sensitivity (M/I) (r = 0.46 p = 0.02) and age (r = -0.46 p = 0.02), which together explained almost half of the variance in PF%RF (adjusted r² = 0.37, p = 0.008). Whilst atorvastatin decreased LDL cholesterol by 51% (p < 0.001), PF%RF and flowmotion remained unchanged. CONCLUSIONS:Insulin sensitivity and age are independently associated with an insulin-induced change in functional microvascular dilator capacity in individuals with central adiposity at risk of CVD. Dilator capacity is not improved by six months high dose statin treatment.
Authors: Dennis M J Muris; Alfons J H M Houben; Miranda T Schram; Coen D A Stehouwer Journal: Rev Endocr Metab Disord Date: 2013-03 Impact factor: 6.514
Authors: Keith G McCormick; Eleonora Scorletti; Lokpal Bhatia; Philip C Calder; Michael J Griffin; Geraldine F Clough; Christopher D Byrne Journal: Diabetologia Date: 2015-05-29 Impact factor: 10.122
Authors: Caroline C McGown; Zoë L S Brookes; Paul G Hellewell; Jonathan J Ross; Nicola J Brown Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2015-02-14 Impact factor: 3.000
Authors: R Grace Walton; Brian S Finlin; Jyothi Mula; Douglas E Long; Beibei Zhu; Christopher S Fry; Philip M Westgate; Jonah D Lee; Tamara Bennett; Philip A Kern; Charlotte A Peterson Journal: Physiol Rep Date: 2015-06
Authors: Geraldine F Clough; Andrew J Chipperfield; Marjola Thanaj; Eleonora Scorletti; Philip C Calder; Christopher D Byrne Journal: Front Physiol Date: 2020-06-03 Impact factor: 4.566
Authors: Isabelle Ea Pontes; Karine F Afra; José R Silva; Paulo Sn Borges; Geraldine F Clough; João Gb Alves Journal: Diabetol Metab Syndr Date: 2015-03-28 Impact factor: 3.320